Having established that the literature on NOX2 in stroke fulfilled all typical criteria for insufficient pre-clinical target validation (publication bias, poor methodological quality and lack of power), we here present the first SR-MA-pRCT-MA approach to validate a single intervention or, in this case, target validation. The gene discussed is CYBB; the disease is stroke disorder.